We are live on ! Find out more
CANF

Can-Fite BioPharma American Depositary Shares

8 hedge funds and large institutions have $518K invested in Can-Fite BioPharma American Depositary Shares in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

922% more capital invested

Capital invested by funds: $50.7K → $518K (+$467K)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

100% more funds holding

Funds holding: 48 (+4)

0% more ownership

Funds ownership: 0%0% (+0%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
8
Holders Change
+4
Holders Change %
+100%
% of All Funds
0.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
Reduced
2
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CH
1
CVI Holdings
Delaware
$392K +$364K +990 New
VF
2
Virtu Financial
New York
$63K +$58.5K +159 New
Envestnet Asset Management
3
Envestnet Asset Management
Illinois
$24K +$22.5K +61 New
TSS
4
Two Sigma Securities
New York
$20K +$18.4K +50 New
Morgan Stanley
5
Morgan Stanley
New York
$8K -$11.8K -32 -63%
UBS Group
6
UBS Group
Switzerland
$6K -$10.3K -28 -65%
PAG
7
Private Advisor Group
New Jersey
$4K +$3.68K +10 New
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.05K
Citadel Advisors
9
Citadel Advisors
Florida
-$26K -101 Closed

CANF Hedge Fund Activity: Q2 2020 in Review

8 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2020, worth a combined $518K — up 922% from $50.7K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CANF positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was CVI Holdings, opening a new position worth an estimated $364K. The largest seller was Citadel Advisors, exiting entirely with an estimated $26K sold.

  • 8 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2020, up from 4 in Q1 2020.
  • Funds reported $518K of Can-Fite BioPharma American Depositary Shares stock for Q2 2020, up 922% quarter-over-quarter.
  • 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2020 and 1 closed out, a net change of +4 holders.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2020 was CVI Holdings, an estimated $364K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2020 was Citadel Advisors, an estimated $26K sold.

Based on aggregated 13F filings for Q2 2020.